Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02450851 |
Recruitment Status :
Recruiting
First Posted : May 21, 2015
Last Update Posted : June 2, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background:
- Without an explanation for severe and sometimes life-threatening symptoms, patients and their families are left in a state of unknown. The NIH helped create a network of medical research centers, called the Undiagnosed Diseases Network (UDN), to provide care and answers for these individuals.
Objectives:
- To improve diagnosis and care for people with undiagnosed diseases.
Eligibility:
- People with undiagnosed diseases, and their relatives.
Design:
-
Participants will travel to one of the UDN medical centers for a 5-day clinical and research visit.
-
As part of the visit, UDN healthcare providers may ask participants to have:
-
Clinically indicated tests and procedures performed including:
- A physical exam
- Blood and urine tests
- A review of health and family history
- X-rays and body scans
- Surveys
- Photographs of the face and body
- A special diet to see if the body can handle the food without having a reaction, like vomiting
- Video or voice recordings
- Other tests and procedures to help reach a diagnosis
-
Research tests and procedures performed including:
- A skin biopsy. For this, a small piece of skin will be taken.
- Surveys
- Other tests and procedures for research that may not be related to a diagnosis or treatment.
-
-
- Most participants will be asked to give samples for genetic testing.
- Participants may be contacted after their visit to discuss test results. They may also be contacted in the future for interviews and surveys.
- Relatives of participants may be asked to give samples for genetic testing. They may be asked to have parts of their visit recorded and to have additional tests. They may also be contacted in the future for interviews and surveys.
- Clinical and research information collected will be stored in a database.
- Information and samples collected will be shared with others for research purposes....
Condition or disease |
---|
Genetic Disease |
Study Type : | Observational |
Estimated Enrollment : | 16000 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Clinical and Genetic Evaluation of Patients With Undiagnosed Disorders Through the Undiagnosed Diseases Network |
Actual Study Start Date : | September 16, 2015 |
Estimated Primary Completion Date : | December 31, 2028 |
Estimated Study Completion Date : | December 31, 2028 |
Group/Cohort |
---|
Undiagnosed disorders
Patients with rare, undiagnosed disorders.
|
- Improve the level of diagnosis and care for patients with undiagnosed diseases through the development of common and site-specific protocols designed by an enlarged community of investigators [ Time Frame: Inpatient stay Day 1-5 and followup ]Improve the level of diagnosis and care for patients with undiagnosed diseases through the development of common and site-specific protocols designed by an enlarged community of investigators.
- Facilitate research into the etiology of undiagnosed diseases, by collecting and sharing standardized, high-quality clinical and laboratory data including genotyping, phenotyping, and documentation of environmental exposures [ Time Frame: Inpatient stay Day 1-5 and followup ]Facilitate research into the etiology of undiagnosed diseases, by collecting and sharing standardized, high-quality clinical and laboratory data including genotyping, phenotyping, and documentation of environmental exposures.
- Create an integrated and collaborative research community across multiple clinical sites and between laboratory and clinical investigators prepared to investigate the pathophysiology of these new and rare diseases, the impact of the diagnostic p... [ Time Frame: Inpatient stay Day 1-5 and followup ]Create an integrated and collaborative research community across multiple clinical sites and between laboratory and clinical investigators prepared to investigate the pathophysiology of these new and rare diseases, the impact of the diagnostic process on patients and families, and share this understanding to identify improved options for optimal patient management.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Month to 100 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
- INCLUSION CRITERIA:
-
Ideal applicants to the UDN include individuals with:
- One or more objective findings pertinent to the phenotype for which a UDN application was submitted.
- No diagnosis despite evaluation by at least two specialists who assessed the patient for the objective finding(s).
- Agreement for the storage and sharing of information and biomaterials, in an identified fashion amongst the UDN centers, and in a de-identified fashion to research sites beyond the network.
- Applicants unable to consent can be enrolled.
EXCLUSION CRITERIA:
-Applicants who are unlikely to be accepted include individuals with:
- Reported symptoms with no relevant objective findings.
- A diagnosis explaining objective findings.
- A diagnosis suggested on record review.
- Unwillingness to share data.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02450851
Contact: Paul Mazur | (844) 746-4836 | paul_mazur@hms.harvard.edu |

Principal Investigator: | William A Gahl, M.D. | National Human Genome Research Institute (NHGRI) |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | National Human Genome Research Institute (NHGRI) |
ClinicalTrials.gov Identifier: | NCT02450851 |
Other Study ID Numbers: |
150130 15-HG-0130 |
First Posted: | May 21, 2015 Key Record Dates |
Last Update Posted: | June 2, 2023 |
Last Verified: | May 26, 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Rare Diseases Undiagnosed Diseases Natural History |
Genetic Diseases, Inborn Undiagnosed Diseases Disease Attributes Pathologic Processes |